



Press release

Stockholm, April 20, 2010

Interim Report – January to March 2010

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report covering the First Quarter 2010.

Financial Highlights

- Revenue for the 1st Quarter 2010 was SEK 4.8 (5.7) million
- Net loss for the period amounted to SEK -7.8 (-11.9) million
- Earnings per share was SEK -0.11 (-0.40)
- Cash flow from current operations was SEK -8.1 (-13.8) million

Key Corporate Highlights

- During the period Affibody signed an agreement with an undisclosed company regarding its HER2 molecular imaging program, which includes ABY-025.
- Affibody’s proprietary albumin binding technology, Albumod™, has gained interest from several companies searching for a relevant half-life extension technology.
- An EGM held on April 15 resolved a share issue directed to existing shareholders. Fully subscribed the issue will bring SEK 29.5 million gross to the company.

David Bejker CEO, said: *“Affibody has during the first quarter been able to move a number of business development discussions forward while in parallel reduced the financial uncertainty for the company by renegotiating existing agreements. We appreciate the strong support from investors in the ongoing share issue which also highlights the potential of our platforms”.*

Enquiries

David Bejker, CEO
Johan Stuart CFO

+46 706 454 948
+46 706 644 096

About Affibody

Affibody is a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody® molecules, which are small, robust and easily produced, can be designed to bind specifically to a large number of target proteins. They have a broad range of applications including protein purification, enzyme inhibition, research reagents for protein capture and detection, diagnostics, including molecular imaging, and targeted therapeutics.

Affibody is also commercializing its unique albumin binding technology Albumod™, together with own Affibody®- molecules or with other biotherapeutics. The technology is designed to enhance the efficacy of biotherapeutics by extending their circulation time.

Affibody has already developed biotechnological products that are commercialized by GE, Agilent and Finnzymes, and is developing molecules for therapeutic application in collaboration with Biovitrum.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include the investment companies HealthCap and Investor Growth Capital.

Further information can be found at: www.affibody.com



Lindhagensgatan 133, SE-112 51 Stockholm, Sweden.
Tel +46 8 59 88 38 00, Fax +46 8 59 88 38 01, www.affibody.com